# A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

> **NCT03665285** · PHASE1,PHASE2 · COMPLETED · sponsor: **NextCure, Inc.** · enrollment: 109 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Lung Cancer
- Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Endometrial Cancer
- Melanoma
- CRC
- Urothelial Carcinoma
- Cholangiocarcinoma

## Interventions

- **DRUG:** NC318

## Key facts

- **NCT ID:** NCT03665285
- **Lead sponsor:** NextCure, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2023-04-11
- **Final completion:** 2023-04-11
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03665285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03665285, "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03665285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*